Tailored intervention compared to usual care on smoking type 2 diabetic patients to promote smoking cessation and improved glycaemic control

A randomized controlled trial of a tailored intervention compared to usual care on smoking type 2 diabetic patients to promote smoking cessation and improved glycaemic control

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN34551140

Enrollment

758

Registered

2012-03-05

Start date

2012-02-01

Completion date

Unknown

Last updated

2016-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type II diabetes Nutritional, Metabolic, Endocrine Non-insulin-dependent diabetes mellitus

Interventions

The intervention group will receive education materials about smoking cessation, and a 30-minute face-to-face smoking cessation counselling conducted by a trained nurse smoking cessation counsellor at

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Smokes at least 2 cigarettes daily in the past 30 days 2. Diagnosed with type 2 diabetes for at least 6 months such that their diabetic conditions and treatments should be stable 3. Age 18 or above 4. Can communicate in Cantonese

Exclusion criteria

Exclusion criteria: 1. Too sick to receive intervention 2. Poor cognitive state 3. Mental illness 4. Undergoing other smoking cessation program 5. With unstable diabetic or other medical conditions deemed to be not suitable by the doctor in charge

Design outcomes

Primary

Measure	Time frame
Self-reported 7-day tobacco abstinence rate at 12 months	—

Secondary

Measure	Time frame
1. The change in glycated haemoglobin (HbA1c) levels 2. Biochemical validated quitting and changes in smoking behaviors (reduction in cigarette consumption and progression to a higher stage of readiness to quit) 3. Clinical outcomes [body mass index (BMI), sodium, potassium chloride, blood glucose, blood pressure and renal function] and 4. Lifestyle risk factors (drinking, fruit and vegetable intake) Measured at 12 months	—

Measure

Time frame

1. The change in glycated haemoglobin (HbA1c) levels 2. Biochemical validated quitting and changes in smoking behaviors (reduction in cigarette consumption and progression to a higher stage of readiness to quit) 3. Clinical outcomes [body mass index (BMI), sodium, potassium chloride, blood glucose, blood pressure and renal function] and 4. Lifestyle risk factors (drinking, fruit and vegetable intake) Measured at 12 months

—

Countries

Hong Kong

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026